Read the brochure
Emerging Business Tools
Our Life Sciences Transactions Practice assists clients in structuring, negotiating and implementing merger & acquisition, joint venture, strategic alliance, corporate partnering, licensing, financing and outsourcing transactions to help them achieve their business goals. Our ability to also provide the life sciences regulatory, scientific and litigation assessment components necessary to a transaction (including intellectual property, FDA/healthcare regulatory, product liability, outsourcing, tax, antitrust, labor and employment, employee benefits and real estate), uniquely positions us to successfully complete transactions in a coordinated and efficient manner. Representative transactions include:
- FMC Corporation in its acquisition of the Rovral® iprodine and Sportak® prochloraz brand families from Bayer CropScience
- Concordia Pharmaceuticals in the sale to Kadmon Corporation of substantially all its assets, including its rights to the cancer drug Salirasib
- Diversified Service Options, a wholly-owned subsidiary of Blue Cross and Blue Shield of Florida and the holding company for First Coast Service Options, in its acquisition of Highmark Medicare Services, a subsidiary of Highmark
- Independence Blue Cross in its acquisition of AmeriHealth Mercy Family of Companies
- AxoGen Corporation in its reverse triangular merger with LecTec Corporation
- Perrigo Company in the sale of certain marketed pharmaceutical products to Watson Pharmaceuticals
- Alacer Biomedical in its sale to Allergan
- Orchid Cellmark in its sale to LabCorp for $85.4 million
- OnPoint Medical Diagnostics in its reverse merger with Vertical Health Solutions
- Galen Partners in its purchase of a controlling equity stake in Cambrooke Foods, a pharma foods company
- Embrella Cardiovascular in its $43 million sale to Edwards Life Sciences
- Axcan Pharma in its sale of the pharmaceutical products, Photofrin and Photobarr, to Pinnacle Biologics
- ARAMARK Healthcare in its acquisition of Masterplan
- Perrigo in its $540 million acquisition of Paddock Laboratories
- medSage in its sale to Respironics, a division of Philips Electronics
- Eurand in its $538 million sale to Axcan Holdings
- Sofinnova Partners in the sale of Preglem to Gedeon Richter for €337 million
- BMP Sunstone in its sale to sanof-aventis for $526 million
- Safeguard Scientifics in the sale of its partner company Clarient to GE Healthcare for $587 million
- Solstice Neurosciences in its sale to US WorldMeds for $35 million
- InfuSystem Holdings in its acquisition of First Biomedical for $17.2 million
- ViroPharma in its ₤20 million acquisition of Auralis
- Valeant Pharmaceuticals in its acquisition of Aton Pharma for $318 million
- BioClinica in its acquisition of TranSenda International
- Biovail in its acquisition of certain AMPAKINE® compounds and associated intellectual property from Cortex Pharmaceuticals
- Perrigo Company in its acquisition of PBM Products for $808 million
- The investors of Novexel including Sofinnova Partners, Atlas Venture, Novo AS, Edmond de Rotschild Investment Partners, Daiwa SMBC Capital Co, NeoMed, Abingworth and Goldman Sachs in the sale of Novexel to AstraZeneca for $505 million
- BioClinica in its acquisition of Tourtellotte Solutions and CardioNow
- Medical Imaging Holdings in its acquisitions of Sonora Medical Systems, Barrington Medical Imaging, and Echoserve
- Abingworth, Crédit Agicole Private Equity, Fobion, Gimv, Sofinnova, Veslius, and Wellcome Trust, as investors of Fovea Pharmaceuticals, in its $562 million sale to Sanofi-Aventis
- Leo Pharma in its re-acquisition of U.S. rights to its topical psoriasis treatments from Warner Chilcott for approximately $1 billion
- PeriGen in is acquisition of LMS Medical Systems
- Pierrel Research in its acquisition of Encorium Group
- Chiesi Farmaceutici in its $70 million strategic transaction with Cornerstone Therapeutics
- Biovail Laboratories International SRL in its $510 million acquisition from GlaxoSmithKline of U.S. rights for Wellbutrin XL, approved for major depressive disorder and seasonal affective disorder and originally developed by Biovail
- Sekisui America Corporation in its $25.5 million acquisition of American Diagnostica
- CardioNet in its $14 million acquisition of Biotel
- Bio-Imaging Technologies in the sale of its CapMed Division to Metavante Technologies
- GPC Biotech in its merger Agennix to form a new publicly listed company
- Lundbeck in its acquisition of Ovation Pharmaceuticals for $600 million and up to $300 million in contingent payments
- NexMed in its sale of the U.S. rights for its topical alprostadil erectile dysfunction treatment (Alprox) to partner, Warner Chilcott
- PharmaNet Development Group in its sale to JLL Partners for $250 million
- Meridian Healthcare Group in its sale to Lincare for $44 million
- United Drug plc in the acquisition of The Specials Laboratory for $38 million
- Valeant Pharmaceuticals in the acquisition of Dow Pharmaceutical Sciences for $285 million
- RecoverCare in its acquisition of T.H.E. Medical
- Biovail in its acquisition of Prestwick Pharmaceuticals for $100 million
- Neose Technologies in its $43 million sale to Novo Nordisk and BioGenix
- Nanogen in its acquisition by Elitech Group
- Health Care Service Corporation in the acquisition of MEDecision
- Eli Lilly in the sale for $50 million of a drug development unit to and long-term strategic $1.6 billion services agreement with Covance
- PhotoMedex in its $13 million acquisition of Photo Therapeutics
- Sekisui Chemical Co. in its acquisition of XenoTech valued at $50 million
- Sharp Corporation in its $99 million sale to United Drug plc
- Barrier Therapeutics in its $148 million sale to Stiefel Laboratories
- Catalent Pharma Solutions in the sale of its New Mexico pharmaceutical laboratory to Oso Biopharmaceuticals Manufacturing
- EP MedSystems in its acquisition by St. Jude Medical for $92.1 million
- Bio-Imaging Technology in its acquisition of Phoenix Data Systems for $22 million
- Cytogen in its acquisition by EUSA Pharma for $22.6 million
- AmerisourceBergen in its acquisition of Bellco Drug Corp for $190 million
- Oncology Therapeutics Network (OTN), a portfolio company of One Equity Partners, in its sale to McKesson for $575 million
- New Brunswick Scientific in its sale to the Eppendorf Group for $110 million
- Perrigo Company in its acquisition of Glades Pharmaceuticals
- Wockhardt Limited in its acquisition of Radiant Research
- VIASYS Healthcare in its sale to Cardinal Health for $1.5 billion
- Merck in its divestiture of several marketed products to Iroko Pharmaceuticals
- Sierra Health Services in its sale to UnitedHealth Group for $2.6 billion
- Bio Imaging Technology in its acquisition of Theralys SA
- BioRexis Pharmaceutical in its acquisition by Pfizer
- Cytogen in the sale of its 50% joint venture interest in PSMA Development Company LLC to Progenics
- CMS Private Equity Fund in its acquisition of Med-Dispense
- Provid Pharmaceuticals in its acquisition of Tripos Discovery Research
- Lundbeck in its acquisition of Saegis Pharmaceuticals
- Sun Capital Partners in its $17 million acquisition of Respiratory Distributors
- HAPC in its acquisition of InfuSystem for $140 million
- GNI Ltd. in its acquisition of a controlling interest in Shanghai Genomics in part through the required auction process to purchase the shares of state-owned entities
- United Drug plc in its combined $50 million acquisition of Endoscopy Limited
- OTN in its acquisition of the oncology distribution unit of Cardinal Health
- Nanogen its acquisition of Amplimedical S.p.A.
- Meridian Health Care Group and subsidiary Primedica in the acquisition of Symphony Respiratory Care
- Schering-Plough in its acquisition of Bayer AG’s primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
- Med-Design in its sale to Specialized Health Products International
- Nanogen in its acquisition of Spectral Diagnostics-Rapid
- Laureate Pharma in its acquisition by Discovery Pharmaceuticals
- Biophan Technologies in its acquisition of interest in Myotech
- Duramed Pharmaceuticals in its $156 million acquisition of Mircette desogestrel tablets from Organon International
- Cerenis Therapeutics in its $30 million sale to Sifinnova, Healthcap, Alta Partner, EDF, and NIF, a consortium of French and U.S. venture capital firms
- excelleRX in its acquisition by Omnicare
- InKine Pharmaceutical in its sale to Salix Pharmaceuticals
- United Drug plc in its acquisitions of In2Focus Development Services, TD Packaging, and Presearch Limited
- Femme Pharma Global Healthcare in its divestiture of its Danazol® product to KV Pharmaceuticals
- One Equity Partners in its acquisition from Bristol-Myers Squibb of Oncology Therapeutics Network
- Biovail in its more than $100 million divestiture of its Teveten® and Teveten HCT® products and sale of the marketing rights of its Cardizem®LA product to Kos Pharmaceuticals
- Viscogliosi Brothers in its acquisition of Fixano France
- Smiths Group plc in its $925 million acquisition of Medex
- Perrigo Company in its $818 million cash and stock acquisition of Agis Industries Ltd.
- Closure Medical in its $421 million acquisition by Johnson & Johnson
- Viasys Holdings in its acquisition of the medical division of Oxford Instruments plc for $24 million
- Barrier Therapeutics in its acquisition of the rights to Solage topical solution from Moreland Enterprises
- Sanofi-Aventis in the divestiture of Campto® to Pfizer
- Nanogen in its acquisition of SynX
- Esperion in its acquisition by Pfizer for $1.3 billion
- United Drug plc in its $11 million acquisition of Mantis Surgical Limited
- Cell Pathways in its stock-for-stock acquisition by OSI Pharmaceuticals
- 3-Dimensional Pharmaceuticals in its acquisition by Johnson & Johnson
- Enzon in its acquisition of Abelcet® product rights and related manufacturing facility and other assets from Elan for $370 million
- Pharmacia in the divestiture of its late stage compound to Nastech in connection with its then proposed merger with Pfizer
- Principia in its stock-for-stock acquisition by Human Genome Sciences
- Cephalon in its $444 million stock-for-stock acquisition of Anesta